Congress expands China investment screening to biotech—but leaves rules undefined
S. 5316 — BINSA Act · Filed by Pete Ricketts (R-NE) · 1 cosponsor · Introduced Aug 6, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands the Defense Production Act to treat biotechnology (pharmaceuticals, biologics, drug discovery, clinical research) as a 'prohibited' or 'notifiable' technology for purposes of outbound investment screening. It requires the Treasury and State Departments to issue rules within one year defining which biotech transactions to China require government approval or notification, with particular focus on licensing deals, joint ventures, and equity investments that transfer drug-development know-how or manufacturing capability to Chinese firms. The stated purpose is to prevent U.S. capital and intellectual property from accelerating China's dominance of the pharmaceutical innovation supply chain.
Why we flagged it
The bill's core function is to expand the Defense Production Act's outbound investment review authority to cover biotechnology transactions with China. It is not a subsidy, tax provision, or direct appropriation—it is a regulatory control mechanism. The character reflects its true operational nature: a screening and approval regime for cross-border biotech capital flows.
What the text implies
- The bill delegates core definitional authority to the Treasury/State Departments via rulemaking, leaving the scope of 'prohibited' and 'notifiable' biotech transactions undefined until after enactment. This creates regulatory uncertainty for U.S. biotech companies and investors, potentially chilling legitimate partnerships and licensing deals with non-Chinese foreign entities if rules are written
- Licensing transactions are explicitly flagged as a priority category for screening. This may effectively block or delay U.S. biotech firms from licensing drug-discovery platforms, clinical-trial data, or manufacturing know-how to any foreign partner, not just China, if regulators interpret 'covered foreign person' expansively or if companies avoid foreign licensing altogether to sidestep review.
The full analysis lists 5 implications of this text.
Who stands to gain
U.S. pharmaceutical and biotech companies (reduced competition from Chinese firms, potential price-s; U.S. biotech venture capital and private equity (reduced outbound capital flows may increase domesti